Visit http://indiaer.blogspot.com/ for complete details Elder Pharma (Rating – Buy; Target Price – Rs487)
We expect the topline to grow by 15.5% to Rs2bn on the basis of their presence in fast-growing
niche segments in the domestic market.
EBIDTA margin is expected to improve by 50bps to 19.2%
We expect the company to report adjusted PAT of Rs171mn
No comments:
Post a Comment